IP Library Granted Patent US 10,188,630
Granted Patent B2
US 10,188,630 · App. 15/712,849 · Granted Jan 29, 2019

Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells

Inventors: Carla Grandori (Seattle, WA); Masafumi Toyoshima (Seattle, WA)
Assignee: Fred Hutchinson Cancer Research Center
A61K31/404A61K31/506A61K31/519A61K33/24A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,188,630
App. No.
15/712,849
Granted
Jan 29, 2019
Kind
B2
Abstract

In one aspect, the invention provides a method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor. In another aspect, the invention provides a method of treating a subject suffering from a tumor comprising myc-driven tumor cells, comprising administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells.

Claims (11)

1. A method of treating a subject having a tumor comprising tumor cells of neural origin that overexpress Myc, comprising:

determining that the tumor comprises tumor cells that overexpress Myc; and

then administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells.

2. The method of claim 1 , wherein the tumor is a primary neuroblastoma tumor, a metastatic neuroblastoma tumor, or a brain tumor.

3. The method of claim 1 , wherein the tumor is a primary neuroblastoma tumor or a metastatic neuroblastoma tumor.

4. The method of claim 1 , wherein the subject is further provided one or more additional anti-cancer therapies.

5. The method of claim 4 , wherein the additional anti-cancer therapy comprises chemotherapy.

6. The method of claim 5 , wherein the tumor cells that overexpresses Myc are resistant to cisplatin, and the CSNK1ε inhibitor renders the cell susceptible to cisplatin.

7. The method of claim 1 , wherein the CSNK1ε inhibitor is a small molecule inhibitor.

8. The method of claim 7 , wherein the CSNK1ε inhibitor is selected from the group consisting of IC261, PF-4800567, and PF-670462.

9. The method of claim 1 , wherein the Myc is c-Myc or MycN.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded May 23, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: SEATTLE CANCER CARE ALLIANCE
Reel/Frame 060163/0887 →
CHANGE OF NAME Recorded May 23, 2022
From: SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060389/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2018
From: GRANDORI, CARLA; TOYOSHIMA, MASAFUMI
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 044991/0253 →
Continuity (3)
Continuation 13639258
Provisional Application 61321414 · Apr 6, 2010
Related Publication 20180153858A1 · Jun 7, 2018